Revolutionizing Women's Health: OncoVeryx-F, A Breakthrough in Early Cancer Screening

Introduction

Cancer is one of the formidable health challenges in India, with approximately 1 in 9 individuals expected to confront a cancer diagnosis during their lifetime. Among the various types of cancer, women-specific cancers such as breast and gynecologic (endometrial, uterine cervical, and ovarian) cancers top the list, contributing significantly to the morbidity and mortality in urban as well as rural India. Despite advancements in the diagnostic armamentarium, lack of awareness, limited screening methods, and delayed presentation are the principal hurdles. Therefore, novel modalities are an unmet need. However, there is hope on the horizon with the introduction of metabolomics-based techniques for early cancer screening in women.

Routine cancer screening methods including mammography, ultrasound, Pap smear testing, and serum CA125 biomarker assays have limitations, as these modalities often detect cancers only at stages when the patient has physical indications. Moreover, all biomarkers are not prognostic, elevated levels may not always indicate a cancer, leading to false alarms and unnecessary anxiety. Physical screening techniques, while valuable have their constraints often detecting cancers close to near detection than early. Committed to close the cancer care and screening gap, CORE diagnostics with Predomix Technologies have come up with innovative cancer screening test for women.

OncoVeryx-F

OncoVeryx-F is an integrated approach of serum metabolic screening with artificial intelligence (AI)-based analysis to find common patterns in cellular metabolite variations at very initial stages of four women specific cancers - Breast, Endometrial, Ovarian & Cervical. These metabolic signatures offer close look into the oncogenesis process before physical changes manifest in the affected organ. OncoVeryx-F employs an untargeted (Ultra High performance Liquid Chromatography – Mass Spectrometry) /MS (Mass Spectrometry), coupled with machine learning algorithms to detect early-stage cancers with superior sensitivity and specificity. By correlating known metabolites with the tissue of origin of cancer test provides a comprehensive understanding of the disease at asymptomatic stage. More than 10000 metabolites associated with various biological pathways related to oncogenesis are analyzed and correlated with an individual's clinical history, generating a unique y-score indicating cancer status (0/1). A y-score of >0 denotes a cancer-positive status while a y-score of <0 indicates absence of cancer. Moreover, the ability of OncoVeryx-F to provide information on both cancer stage and tissue of origin underscores its comprehensive approach to cancer detection and management. It equips clinicians with the necessary tools to deliver personalized care and improve patient outcomes.

One of the most significant advantages of OncoVeryx-F is its ability to simultaneously detect multiple cancers at early stages, streamlining diagnostic procedures, and reducing cost. The non-invasive nature of the test further enhances its utility, making it acceptable and accessible to a broader population. Furthermore, noteworthy about the high detection accuracy by test obtained for early-stage cancers, which is significantly superior to that of the other approaches being explored to date. Moreso, the unique context of this test development is that samples from Indian Cancer Registries and Biobanks have been sourced to design test making it the closest to the any such innovative approach in cancer genetics for Indian women.? The robustness and accuracy of OncoVeryx-F is potential to revolutionize women's health by enabling early detection and intervention for breast, endometrial, uterine cervical, and ovarian cancers.

Conclusion

In conclusion, OncoVeryx-F represents a significant leap forward in the fight against cancer, offering hope and improved outcomes for women in India and beyond. As we continue to explore innovative approaches in cancer screening and treatment, OncoVeryx-F stands as a beacon of progress, opening new options of personalized, and proactive cancer screening for Indian women. It is the time to embrace the power of metabolomics and AI in our quest to conquer cancer and safeguard the well-being of generations to come. As we continue to push the boundaries of cancer research and innovation, OncoVeryx-F may remain at the forefront with others, offering firm stand in the fight against cancer.

?Contributed by Ruchi Bhajeewala